F S&P 500
5,067.25 +20.75 (+0.41%) F Dow Jones
38,188.00 +119.00 (+0.31%) F Nasdaq
17,532.50 +94.25 (+0.54%) E-mini Russell 2000 Index Futur
2,003.00 +13.30 (+0.67%) Petróleo
79.27 +0.27 (+0.34%) Oro
2,333.70 +22.70 (+0.98%)
Insulet Corporation (PODD)
Fuera de horario:
Insulet Corporation
100 Nagog Park
Acton, MA 01720
United States
978 600 7000
https://www.insulet.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 3,000
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. James R. Hollingshead Ph.D. | President, CEO & Director | 2.88M | N/D | 1963 |
| Ms. Lauren Budden | Group VP, Chief Accounting Officer & Controller | 794.05k | N/D | 1975 |
| Mr. Mark Field | Senior VP & CTO | 954.14k | N/D | 1971 |
| Mr. John Wodick Kapples | Senior VP & General Counsel | 1.02M | N/D | 1960 |
| Ms. Shacey Petrovic | Director & Advisor | 28.57k | N/D | 1973 |
| Mr. Eric Benjamin | Executive VP, Chief Product & Customer Experience Officer | 1.14M | N/D | 1983 |
| Ms. Ana Maria Chadwick | Executive VP, CFO & Treasurer | N/D | N/D | 1972 |
| Mr. Prem Singh | Senior Vice President of Global Operations | N/D | N/D | 1977 |
| Ms. Deborah R. Gordon CPA | Vice President of Investor Relations | N/D | N/D | 1971 |
| Ms. Laetitia Cousin | Senior VP of Regulatory Affairs, Quality Assurance & Compliance | N/D | N/D | 1976 |
Descripción
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Insulet Corporation a partir del 29 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 6; Junta: 5; Derechos del accionista: 10; Compensación: 8.
